SCHEMBL1640771

SCHEMBL1640771

Cc1ccc(Cl)cc1CN

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.52
CYP2A6 P11509 1/20 0.44
TAAR1 Q96RJ0 1/20 0.42
ALDH1A1 P00352 2/20 0.41
PNMT P11086 3/20 0.40
MAPT P10636 2/20 0.40
IDO1 P14902 2/20 0.40
MEN1 O00255 1/20 0.40
SLC22A1 O15245 1/20 0.40
USP2 O75604 1/20 0.40
LMNA P02545 1/20 0.40
HSP90AA1 P07900 1/20 0.40
HSPD1 P10809 1/20 0.40
HSPA5 P11021 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
ALOX12 P18054 1/20 0.40
CASP1 P29466 1/20 0.40
HTT P42858 1/20 0.40
BLM P54132 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL31129160 0.98 CYP3A4 (0.50) CYP3A4CYP2A6TAAR1ALDH1A1PNMT
SCHEMBL9479134 0.84 CYP3A4 (0.45) CYP3A4CYP2A6ALDH1A1PNMTMAPT
SCHEMBL13846496 0.83 TAAR1 (0.64) CYP3A4TAAR1ALDH1A1MAPTIDO1
SCHEMBL193074 0.82 CYP3A4 (0.46) CYP3A4CYP2A6ALDH1A1PNMTIDO1
SCHEMBL6588336 0.82 CYP3A4 (0.46) CYP3A4CYP2A6ALDH1A1MAPTIDO1
Hydrochloric Acid SCHEMBL17330388 0.81 TAAR1 (0.62) CYP3A4TAAR1ALDH1A1MAPTIDO1
SCHEMBL31459834 0.79 CYP3A4 (0.48) CYP3A4CYP2A6ALDH1A1MAPTIDO1
SCHEMBL9861809 0.79 CYP3A4 (0.48) CYP3A4CYP2A6ALDH1A1MAPTIDO1
SCHEMBL8418306 0.79 CYP3A4 (0.48) CYP3A4TAAR1ALDH1A1MAPTIDO1
SCHEMBL701343 0.78 CYP2A6 (0.48) CYP3A4CYP2A6TAAR1ALDH1A1PNMT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118702581-A Efficient separation method of 3-chloro-2-methylaniline and 5-chloro-2-methylaniline 上海鲲博玖瑞医药科技发展有限公司 2024-09-27 CN claimed
EP-2906559-B1 AZAINDOLINES HOFFMANN LA ROCHE (CH) 2017-02-08 EP claimed
EP-1831206-B1 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARM INC (US) 2011-08-24 EP claimed
EP-1610779-B1 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS LILLY CO ELI (US) 2009-09-09 EP claimed
JP-2008521903-A 2008-06-26 JP claimed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 EP claimed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 WO claimed
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library OSI PHARMACEUTICALS, INC. 2006-06-01 US claimed
CN-117105800-B Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2025-06-24 CN disclosed
CN-118702581-A Efficient separation method of 3-chloro-2-methylaniline and 5-chloro-2-methylaniline 上海鲲博玖瑞医药科技发展有限公司 2024-09-27 CN disclosed
CN-117105800-A Pendimethalin hapten, pendimethalin antigen, pendimethalin antibody and preparation method and application of pendimethalin hapten, pendimethalin antigen and pendimethalin antibody 贵州国芯生物科技有限公司 2023-11-24 CN disclosed
US-20230364032-A1 USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS VANDERBILT UNIVERSITY 2023-11-16 US disclosed
US-20230355549-A1 METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS VANDERBILT UNIVERSITY 2023-11-09 US disclosed
US-20230330049-A1 COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER MTI BIOTECH, INC. 2023-10-19 US disclosed
US-6515011-B2 Anticoagulants MERCK & CO., INC. 2003-02-04 US disclosed
EP-1259506-A1 PYRAZINONE THROMBIN INHIBITORS Merck & Co., Inc. (US) 2002-11-27 EP disclosed
US-20020119992-A1 Thrombin inhibitors MERCK & CO., INC. 2002-08-29 US disclosed
WO-2002050056-A1 BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS MERCK & CO., INC. (US) 2002-06-27 WO disclosed
US-6387911-B1 Pyrazinone thrombin inhibitors MERCK & CO., INC. 2002-05-14 US disclosed
WO-2001038323-A1 PYRAZINONE THROMBIN INHIBITORS MERCK & CO., INC. (US) 2001-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020119992-A1 Thrombin inhibitors SERPINC1, F2, TFPI CYP3A4 1979/4885CYP2A6 3469/4885TAAR1 3437/4885
US-20230364032-A1 USE OF 2-HOBA TO TREAT ATHEROSCLEROSIS HACL2, APOB, OAT CYP3A4 4366/4885CYP2A6 2047/4885TAAR1 3700/4885
US-20230355549-A1 METHOD OF PREVENTING KIDNEY INJURY DISRUPTION OF INTESTINAL LYMPHATICS FABP2, SI, MLN CYP3A4 3794/4885CYP2A6 2656/4885TAAR1 4642/4885
US-20230330049-A1 COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER GGT1, GGH, AKR7A2 CYP3A4 2680/4885CYP2A6 1473/4885TAAR1 1641/4885
US-20060116402-A1 N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library KIT, CHUK, TNNI3K CYP3A4 3141/4885CYP2A6 4453/4885TAAR1 4483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.